OncoMatch/Clinical Trials/NCT03933670
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
Is NCT03933670 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Hyperpolarized Carbon C 13 Pyruvate for prostate adenocarcinoma.
Treatment: Hyperpolarized Carbon C 13 Pyruvate — This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received treatment. Diagnostic procedures, such as MRI, may help visualize HP C-13 pyruvate uptake and breakdown in tumor cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: androgen deprivation therapy (luteinizing hormone-releasing hormone (LHRH) analogue, oral anti-androgen therapy)
Exception: Previous use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least 28 days prior to baseline C-13 HP pyruvate MRI
Current or prior androgen deprivation therapy including luteinizing hormone-releasing hormone (LHRH) analogue or oral anti-androgen therapy. Previous use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least 28 days prior to baseline C-13 HP pyruvate MRI
Cannot have received: radiation therapy
Prior radiation treatment of the prostate
Lab requirements
Blood counts
ANC >= 1000/uL; Hemoglobin >= 9.0 g/dL; Platelets >= 75,000/uL
Kidney function
Estimated creatinine clearance >= 50 mL/min by Cockcroft Gault equation
Liver function
Total bilirubin <= 1.5 x ULN or <= 3 x ULN if known/suspected Gilbert's; AST <= 1.5 x ULN; ALT <= 1.5 x ULN
Cardiac function
No congestive heart failure with NYHA status >= 2; Poorly controlled hypertension (> 160 mm Hg systolic or > 100 mm Hg diastolic) excluded
ANC >= 1000 cells/microliter (uL). Hemoglobin >= 9.0 gm/deciliter (dL). Platelets >= 75,000 cells/uL. Estimated creatinine clearance >= 50 mL/min by the Cockcroft Gault equation. Total bilirubin <= 1.5 x ULN or <= 3 x ULN if known/suspected Gilbert's. AST <= 1.5 x ULN. ALT <= 1.5 x ULN. Poorly controlled hypertension, with blood pressure at study entry > 160 mm Hg systolic or > 100 mmg Hg diastolic. Congestive heart failure with New York Heart Association (NYHA) status >= 2.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify